OTHER GROUP COMPANIES
market

Tatva Chintan Pharma Chem posts 9% yoy higher Q3 PAT at Rs22.8cr

The company has reported revenue from operations of Rs104.67cr during the period ended December 31, 2021, 31% higher yoy.

January 18, 2022 9:18 IST | India Infoline News Service
Tatva Chintan Pharma Chem Limited, an integrated speciality chemical company, has reported consolidated financial results for the third quarter and nine months ended December 31, 2021. The company has reported revenue from operations of Rs104.67cr during the period ended December 31, 2021, 31% higher yoy as compared to Rs80.117cr in the same period of last fiscal.

The company has posted a net profit of Rs22.807cr for Q3FY22, 9% higher yoy as against a net profit of Rs20.875cr in Q3FY21.EBITDA for the quarter was Rs28.532cr, higher by 13% yoy. EBITDA margin for the quarter was at 27.26%.

The company stock was under pressure on Tuesday and at around 9.22 AM, Tatva Chintan Pharma Chem Ltd was trading at Rs2,666.65 per share down by Rs201.35 or 7.02% from its previous closing of Rs2,868 per share on the BSE.

The company has reported EPS of Rs10.29 for the period ended December 31, 2021 as compared to Rs10.39 for the period ended December 31, 2020.

For the nine months ended of the current fiscal, the company has reported revenue from operations of Rs335.117cr, higher by 75% yoy. The company has posted net profit of Rs78.364cr for the nine months’ period ended December 31, 2021, 152% higher yoy as against net profit of Rs31.143cr for the 9 Months period ended December 31, 2020.

The company has reported EPS of Rs.36.82 for the 9 Months period ended December 31, 2021 as compared to Rs.15.50 for the 9 Months period ended December 31, 2020.

“We are very well on our way of being recognised as a niche player in the specialty chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma a& Agrochemical Intermediates and Specialty Chemicals with PTC comprising 24% SDAs comprising 51% Electrolyte Salts comprising 2% and pASC comprising 22% of the revenue taking the revenuetill date i.e. 9MFY22 at Rs3,351.17 million as compared to 3,003.59 million during FY21.

The company posted an EBITDA margin of 28.30% during 9MFY22 as compared to 23.85% during FY21. During the quarter, exports comprised 80% of the revenue,” Chintan Shah, Managing Director of the company said.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity